Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
We use essential cookies by default: sign-in, your choice in this banner (supstack-consent) and your language (NEXT_LOCALE). Vercel Web Analytics (cookieless page counts) and Sentry error reports (without replay) run either way. Only if you choose "Accept all" do we also create a browser ID in local storage (it ties your visits together in our site records), record error-replay diagnostics (Sentry: masked DOM snapshots, only when an error fires) and turn on load-time metrics (Vercel Speed Insights) so we can fix slow pages faster. Learn more about cookies
Urea doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2026 with a typical study size of 60 participants.
Based on 12 studies · 3 meta-analyses · 8 RCTs · 8,476 total participants
Study base
12 studies indexed
By outcome
Every outcome below: Too few graded studies.
Skin healthSignificant improvement in xerosis signs over 4 weeks, though not reliably better than a plain cheap moisturiser · 2-4 weeks · Reduced scaling and hyperkeratosis in ichthyosis and hyperkeratotic skin; removes scale before other treatments at 30% · 4-8 weeks2 studies
2 studies
Hair & nails2 studies
2 studies
Safety profile1 study
1 study
Active research area
8 studies in the last 5 years · Latest meta-analysis: 2025
199820122026
1Meta-AnalysisCited 206×n=6,603 · very large study2017
In plain English: Moisturiser use yielded a lower SCORAD than no moisturiser across three studies and 276 participants, but the minimal important difference was UNMET.
van Zuuren EJ, et al. · Cochrane Database Syst Rev (2017)
The Cochrane review that sets the context urea has to be judged in: 77 studies, 6603 participants.
Statistically present, clinically small: SCORAD improved but the minimal important difference was not met.
Moisturisers prolonged time to flare, reduced flare numbers and reduced the topical corticosteroid needed — findings the review grades as low to moderate quality.
2Meta-Analysis2025
In plain English: Topical 40% urea can be used to improve the clinical efficacy of antifungals for onychomycosis.
Kurniasari FT, Ervianti E, Damayanti, Wungu CDK, Murtiastutik D, Indramaya DM, Anggraeni S, Avicenna F. · Mycoses (2025)
However, there were no significant differences in mycological and total cure rates (OR: 1.71; 95% CI: 0.63-4.61; p > 0.25 and OR 1.23; 95% CI: 0.47-3.23; p > 0.5).
Topical 40% urea can be used to improve the clinical efficacy of antifungals for onychomycosis.
However, evidence for mycological and total efficacy is lacking.
In plain English: Across seven trials and 1387 patients, the PROPHYLACTIC subgroup showed significantly lower grade 2 or higher hand-foot syndrome with urea cream (RR 0.72, 95% CI 0.58-0.90), while the reduction in any-grade hand-foot syndrome was not significant (RR 0.79, 95% CI 0.58-1.08).
Chen M, et al. · Cancer Nurs (2022)
Seven trials, 1387 patients, PROSPERO-registered. Both risk ratios below come from the prophylactic subgroup, not the whole pool.
The significant result is for SEVERE disease: grade 2 or above, RR 0.72 (95% CI 0.58-0.90).
Any-grade hand-foot syndrome was not significantly reduced: RR 0.79 with a confidence interval crossing 1 (0.58-1.08).
4RCTCited 2×n=216 · medium study2025
In plain English: Any-grade hand-foot syndrome was reported by 68 of 109 patients (62.4%) on usual care and 60 of 107 (56%) using urea cream (p = 0.36); grade 3 occurred in 47.7% versus 41.1% (p = 0.34).
Sookprasert A, et al. · BMC Cancer (2025)
THE COUNTER-EVIDENCE: a 216-patient randomised trial in which every prespecified endpoint was null.
Every endpoint was null: any-grade HFS 62.4% vs 56% (p = 0.36), grade 3 47.7% vs 41.1% (p = 0.34), capecitabine modification 18.3% vs 15.9% (p = 0.89), and similar time to onset.
The authors’ own summary: urea cream "did not prevent capecitabine-associated HFS, reduce capecitabine modification, and delay HFS onset".
5RCTCited 11×n=40 · small study2024
In plain English: Preparing the skin at home with keratolytics including 30% urea cream, instead of curettage, gave a -54.7% lesion reduction against -58.7% with curettage, with no statistically significant difference in efficacy or patient satisfaction.
Tests urea’s KERATOLYTIC property as a substitute for a painful procedure — removing scale so a photosensitiser can penetrate.
The comparator is curettage, which patients find painful and which causes stinging when the photosensitiser is applied to freshly curetted skin.
The result is a NULL and that is the point: -54.7% without curettage versus -58.7% with it, and the differences in efficacy and patient satisfaction were not statistically significant.
6RCTCited 2×n=41 · small study2018
In plain English: Comparing 25% urea cream with sorbolene over 28 days, both improved foot xerosis significantly, and the difference between them was not significant (effect size -0.48, 95% CI -1.16 to 0.22).
Parker J, et al. · J Am Podiatr Med Assoc (2018)
The price question, asked directly: 25% urea cream against plain sorbolene, a basic cheap moisturiser.
Both worked. Mean improvement 3.50 (95% CI 2.80-4.20) for urea and 2.90 (95% CI 2.00-3.80) for sorbolene.
The difference was not significant (P ≤ .09; effect size -0.48, 95% CI -1.16 to 0.22).
7Observational2026
In plain English: This study has provided strong evidence for the potential use of U10% emollient as a highly effective solution tailored to meet the unique needs of age-related xerosis and pruritus.
Lee Seifert C, Gewiss C, Meineke A, Kerob D, Le Floc Apos H C, Augustin M. · Skin pharmacology and physiology (2026)
This study has provided strong evidence for the potential use of U10% emollient as a highly effective solution tailored to meet the unique needs of age-related xerosis and pruritus.
In plain English: In 60 children treating one side with 10% urea lotion and the other with the urea-free lotion base, global severity fell from 4.8 to 2.0 on the urea side and from 4.8 to 2.5 on the base side, with 8-week response rates of 78% and 72%.
Küster W, et al. · Dermatology (1998)
A strong design for a small study: SEMILATERAL, so each child is their own control, with an untreated control area on each side as well.
Urea beat its own vehicle — 4.8 to 2.0 versus 4.8 to 2.5 on a visual analogue scale over 8 weeks.
The margin is narrow: 8-week response rates were 78% for the urea lotion against 72% for the plain lotion base, and the vehicle moved severity from 4.8 to 2.5 on its own.
9RCT2025
In plain English: The novel skin barrier repair cream provides a comparably effective treatment for pedal fissures without additional side effects.
Ross AJ, Pereira J, Moellmer R, Hubbard C, Deogracias RT, Zahid F. · Journal of the American Podiatric Medical Association (2025)
Significant improvement in function was observed in the group treated with the novel skin barrier repair cream.
The results showed minimal statistical difference in healing between the novel skin barrier repair cream and urea 40% across all measured parameters.
The novel skin barrier repair cream provides a comparably effective treatment for pedal fissures without additional side effects.
In plain English: At 24 weeks, SCIO response rates were 42.86% for laser alone, 66.67% for urea occlusion alone and 61.11% for the combination; mycological cure rates were 26.52%, 53.33% and 56.52% respectively.
Wang Y, et al. · Lasers Med Sci (2025)
Places urea occlusion against a device therapy, with twice-daily miconazole given to EVERY arm.
Urea occlusion alone was numerically higher than laser alone on SCIO response (66.67% vs 42.86%) and mycological cure (53.33% vs 26.52%), but that between-group gap was NOT among the differences reported as significant — the abstract’s own conclusion favours the combination.
The antifungal is common to all three arms, so this measures urea occlusion as a penetration-enhancing adjunct, not as a treatment on its own.
11RCTCited 18×n=60 · small study1998
In plain English: A cream combining 2% butenafine hydrochloride with 20% urea cured 88% of big-toenail onychomycosis against 0% on placebo (p < 0.0001), with no relapse among cured patients over a year of follow-up.
Syed TA, et al. · J Dermatol (1998)
Read the combination carefully: butenafine is the antifungal. Urea is there at 20% for keratinolysis, softening the nail so the drug can reach the infection.
The result is striking (88% vs 0%, p < 0.0001) but it is evidence for the combination, NOT for urea curing a fungal infection.
60 patients with more than 25% big-toenail involvement, applied twice daily under occlusion for one week.
12RCTCited 1×n=10 · very small study2024
In plain English: In 20 feet belonging to 10 patients with diabetic foot syndrome, 19 feet (95%) showed improved skin quality after either of two 10% urea creams purchased from pharmacies and supermarkets — the authors conclude they improve foot skin quality "regardless of their cost".
Lázaro-Martínez JL, et al. · Adv Skin Wound Care (2024)
The practical question asked directly, and the conclusion is explicit: creams containing 10% urea purchased in SUPERMARKETS improve foot skin quality "regardless of their cost".
Reduced xerosis, hyperkeratosis and preulcerative signs such as subkeratotic bruising and redness on the dorsum of the toes.
Very small: 10 patients, 20 feet, single centre. Treat it as a pilot.